Kutzkey Tim
CIK 0001614186 Name as filed on the most recent filing
Filed as Kutzkey Tim (89)
246 transaction lines · from 89 filings · filed 2017-10-30 to 2026-02-26 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Tenaya Therapeutics, Inc. 3 filings
- ISSUER Eikon Therapeutics, Inc. 1 filings
- ISSUER Surrozen, Inc./DE 7 filings
- ISSUER NGM Biopharmaceuticals Inc 62 filings
- ISSUER Rapt Therapeutics, Inc. 11 filings
- ISSUER Constellation Pharmaceuticals Inc 3 filings
- ISSUER Revolution Medicines, Inc. 1 filings
- ISSUER Immune Design Corp. 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
22 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2022-11-04 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 35,058 acquired | 4.72 | 165,319.50 | Form 4, filing 0000899243-22-035274 | |
| 2022-11-03 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 104,090 acquired | 4.99 | 519,107.24 | Form 4, filing 0000899243-22-035274 | |
| 2022-10-27 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 76,877 acquired | 4.86 | 373,637.60 | Form 4, filing 0000899243-22-034559 | |
| 2022-10-26 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 72,774 acquired | 4.85 | 353,041.23 | Form 4, filing 0000899243-22-034352 | |
| 2022-10-25 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 51,046 acquired | 4.75 | 242,386.83 | Form 4, filing 0000899243-22-034352 | |
| 2022-06-09 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 951,684 acquired | 13.50 | 12,847,734.00 | Form 4, filing 0000899243-22-022212 | |
| 2022-06-09 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 32,477 acquired | 13.50 | 438,439.50 | Form 4, filing 0000899243-22-022212 | |
| 2022-06-02 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 33,071 acquired | 13.03 | 431,024.26 | Form 4, filing 0000899243-22-021215 | |
| 2022-06-02 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 1,129 acquired | 13.03 | 14,714.60 | Form 4, filing 0000899243-22-021215 | |
| 2022-06-01 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 88,964 acquired | 13.45 | 1,196,565.80 | Form 4, filing 0000899243-22-020688 | |
| 2022-06-01 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 3,036 acquired | 13.45 | 40,834.20 | Form 4, filing 0000899243-22-020688 | |
| 2022-05-31 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 59,766 acquired | 13.47 | 804,797.00 | Form 4, filing 0000899243-22-020688 | |
| 2022-05-31 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 2,040 acquired | 13.47 | 27,470.23 | Form 4, filing 0000899243-22-020688 | |
| 2022-05-27 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 2,621 acquired | 13.45 | 35,255.86 | Form 4, filing 0000899243-22-020202 | |
| 2022-05-27 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 89 acquired | 13.45 | 1,197.17 | Form 4, filing 0000899243-22-020202 | |
| 2022-05-26 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 19,534 acquired | 13.49 | 263,582.03 | Form 4, filing 0000899243-22-020202 | |
| 2022-05-26 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 667 acquired | 13.49 | 9,000.16 | Form 4, filing 0000899243-22-020202 | |
| 2022-05-25 |
Rapt Therapeutics, Inc. RAPT |
P, Open-market purchase | 1,837 acquired | 12.45 | 22,879.65 | Form 4, filing 0000899243-22-019937 | |
| 2022-05-25 |
Rapt Therapeutics, Inc. RAPT |
P, Open-market purchase | 63 acquired | 12.45 | 784.66 | Form 4, filing 0000899243-22-019937 | |
| 2022-05-25 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 41,863 acquired | 13.43 | 562,425.22 | Form 4, filing 0000899243-22-019689 | |
| 2022-05-25 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 1,429 acquired | 13.43 | 19,198.47 | Form 4, filing 0000899243-22-019689 | |
| 2022-05-24 |
Rapt Therapeutics, Inc. RAPT |
P, Open-market purchase | 15,776 acquired | 12.00 | 189,345.13 | Form 4, filing 0000899243-22-019470 | |
| 2022-05-24 |
Rapt Therapeutics, Inc. RAPT |
P, Open-market purchase | 538 acquired | 12.00 | 6,457.13 | Form 4, filing 0000899243-22-019470 | |
| 2022-05-24 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 17,240 acquired | 13.37 | 230,464.32 | Form 4, filing 0000899243-22-019689 | |
| 2022-05-24 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 588 acquired | 13.37 | 7,860.38 | Form 4, filing 0000899243-22-019689 | |
| 2022-05-23 |
Rapt Therapeutics, Inc. RAPT |
P, Open-market purchase | 9,898 acquired | 12.50 | 123,718.07 | Form 4, filing 0000899243-22-019470 | |
| 2022-05-23 |
Rapt Therapeutics, Inc. RAPT |
P, Open-market purchase | 338 acquired | 12.50 | 4,224.76 | Form 4, filing 0000899243-22-019470 | |
| 2022-05-20 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 18,406 acquired | 13.48 | 248,068.71 | Form 4, filing 0000899243-22-019208 | |
| 2022-05-20 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 628 acquired | 13.48 | 8,463.93 | Form 4, filing 0000899243-22-019208 | |
| 2022-05-19 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 19,984 acquired | 13.25 | 264,881.92 | Form 4, filing 0000899243-22-019208 | |
| 2022-05-19 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 682 acquired | 13.25 | 9,039.71 | Form 4, filing 0000899243-22-019208 | |
| 2022-05-18 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 60,583 acquired | 13.20 | 799,931.87 | Form 4, filing 0000899243-22-018848 | |
| 2022-05-18 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 2,067 acquired | 13.20 | 27,292.46 | Form 4, filing 0000899243-22-018848 | |
| 2022-05-17 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 86,110 acquired | 13.42 | 1,155,346.48 | Form 4, filing 0000899243-22-018848 | |
| 2022-05-17 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 2,939 acquired | 13.42 | 39,432.86 | Form 4, filing 0000899243-22-018848 | |
| 2022-05-16 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 32,072 acquired | 12.90 | 413,776.91 | Form 4, filing 0000899243-22-018399 | |
| 2022-05-16 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 1,094 acquired | 12.90 | 14,114.24 | Form 4, filing 0000899243-22-018399 | |
| 2022-05-13 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 125,096 acquired | Not reported | Not priced | Form 4, filing 0000899243-22-018399 | |
| 2022-05-13 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 4,269 acquired | Not reported | Not priced | Form 4, filing 0000899243-22-018399 | |
| 2022-05-12 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 79,945 acquired | 11.62 | 929,048.84 | Form 4, filing 0000899243-22-018030 | |
| 2022-05-12 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 2,728 acquired | 11.62 | 31,702.36 | Form 4, filing 0000899243-22-018030 | |
| 2022-05-12 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 485 acquired | 11.81 | 5,725.76 | Form 4, filing 0000899243-22-018030 | |
| 2022-05-12 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 17 acquired | 11.81 | 200.70 | Form 4, filing 0000899243-22-018030 | |
| 2022-05-11 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 77,866 acquired | 11.23 | 874,108.14 | Form 4, filing 0000899243-22-018030 | |
| 2022-05-11 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 2,657 acquired | 11.23 | 29,826.95 | Form 4, filing 0000899243-22-018030 | |
| 2022-05-11 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 2,564 acquired | 11.85 | 30,376.48 | Form 4, filing 0000899243-22-018030 | |
| 2022-05-11 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 88 acquired | 11.85 | 1,042.56 | Form 4, filing 0000899243-22-018030 | |
| 2022-05-10 |
Rapt Therapeutics, Inc. RAPT |
P, Open-market purchase | 1,208,750 acquired | 10.67 | 12,899,175.62 | Form 4, filing 0000899243-22-017787 | |
| 2022-05-10 |
Rapt Therapeutics, Inc. RAPT |
P, Open-market purchase | 41,250 acquired | 10.67 | 440,199.38 | Form 4, filing 0000899243-22-017787 | |
| 2022-05-10 |
NGM Biopharmaceuticals Inc NGM |
P, Open-market purchase | 30,233 acquired | 11.36 | 343,555.72 | Form 4, filing 0000899243-22-017672 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 22
- Open-market sale 0
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Kutzkey Tim, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001614186
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6